Enterprise Value

159.8M

Cash

145.3M

Avg Qtr Burn

-31.09M

Short % of Float

9.15%

Insider Ownership

1.61%

Institutional Own.

17.98%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
INO-3107 Details
Lung disease, Respiratory conditions, Recurrent respiratory papillomatosis

BLA

Submission

VGX-3100 Details
Anal cancer, Cancer, High-grade squamous intraepithelial lesion

Phase 3

Data readout

INO-5401 + Libtayo Details
Solid tumor/s, Glioblastoma

Phase 2

Update

Phase 1b

Update

INO-5151 Details
Arthritis, Cancer, Prostate cancer

Failed

Discontinued

PENNVAX-GP Details
Human immunodeficiency virus, Sexually transmitted infections

Failed

Discontinued

INO-4800 Details
Infectious disease, COVID-19

Failed

Discontinued

MEDI0457 Details
Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

INO-4700 / GLS-5300 Details
Infectious disease, Middle east respiratory syndrome

Failed

Discontinued

MEDI0457 Details
Cancer, Anal cancer, Cervical cancer

Failed

Discontinued